← Back to all trials
Completed
NCT04869436
Olfactory Outcomes of Dupilumab Treatment for Nasal Polyposis
Conditions: Chronic Rhinosinusitis With Nasal Polyps, Olfactory Disorder
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE4
Enrollment: 15
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Location: St. Joseph's Health Care London Ontario
Summary
The study aims to investigate the olfactory TDI score (Threshold, Discrimination, Identification) using the Sniffin' sticks test for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) on dupilumab. Twenty-seven adult patients will be followed up during the treatment with dupilumab on three visits to the Otolaryngology Clinic (Baseline, 3 months and 6 months).
The primary endpoint will be the TDI score. Nasal polyp score, Quality of Olfactory Disorders - negative symptoms (QOD-NS symptom scores), SNOT-22 will be secondary endpoints.
Eligibility Criteria
Inclusion Criteria:
* Patients older than 18 years old
* Chronic rhinosinusitis with Nasal Polyps
* Olfactory loss
* Clinical indication for treatment with Dupilumab
Exclusion Criteria:
Patients with olfactory loss from other causes such as:
* Sinonasal malignancies
* Trauma
* Idiopathic olfactory loss
* Use of cocaine
* COVID-19 related olfactory loss
* Pregnancy
Source: ClinicalTrials.gov (NCT04869436). StuddyBuddy aggregates publicly available trial information.
